Esophageal Cancer Molecular Diagnostics Market Players:
- Roche Diagnostics
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Siemens Healthineers
- Thermo Fisher Scientific
- Illumina Inc.
- GE Healthcare
- Becton, Dickinson and Company
- Abbott Laboratories Inc.
- bioMérieux
- Agilent Technologies, Inc.
- Hologic, Inc.
- Otsuka Pharmaceutical Co., Ltd
- Chordia Therapeutics
- AI Medical Service
The global burden of oesophageal cancer can be minimized by the collaborative efforts of the various diagnostic companies, alongside the latest medical advancements to tackle the disease. By the day, the technological innovations in the Esophageal Cancer Molecular Diagnostics industry are expected to tackle the malignancy in the earlier stages and push up the survival rate.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of esophageal cancer molecular diagnostics is evaluated at USD 1.61 billion.
The global esophageal cancer molecular diagnostics market size exceeded USD 1.5 billion in 2025 and is set to register a CAGR of around 8.5%, exceeding USD 3.39 billion revenue by 2035.
Asia Pacific esophageal cancer molecular diagnostics market will dominate around 60% share by 2035, driven by limited healthcare access, high inflammation-causing lifestyle, and increasing cancer risk factors.
Key players in the market include Roche Diagnostics, Chordia Therapeutics, Otsuka Pharmaceutical Co., Ltd, Agilent Technologies, Inc., Thermo Fisher Scientific, Illumina Inc..
